top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
COVID-19
COVID-19
Autore Mittal Neeraj
Edizione [1st ed.]
Pubbl/distr/stampa Sharjah : , : Bentham Science Publishers, , 2021
Descrizione fisica 1 online resource (225 pages)
Disciplina 362.1962414
Altri autori (Persone) BhadadaSanjay Kumar
KatareO. P
Soggetto topico Covid-19 vaccines
Public policy
Soggetto non controllato Communicable Diseases
Medical
ISBN 1-68108-805-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Prevention of COVID-19: Facts to Overcome the Myths -- Rajesh Kumar1, Mangesh Pradeep Kulkarni1, Sheetu Wadhwa1 and Soundappan Kathirvel2,* -- INTRODUCTION -- MEASURES TO PREVENT THE SPREAD, ASSOCIATED MYTHS AND FACTS -- Personal Protective Equipment (PPE) -- Head Covers -- Face Shield -- Mask -- Goggles -- Gloves -- Shoe Covers -- Gowns or Coveralls -- SANITIZATION AND DISINFECTION -- Hand Hygiene -- For Public -- Prevention of COVID-19 Among Frontline Healthcare Workers -- Cleaning of Vegetables-Fruits -- Safe Handling of Currency and Paper Documents -- Cough or Respiratory Etiquettes -- Precautions to be Taken While Coughing/Sneezing or Any Physical Contact -- Spitting or Littering in Public -- Disinfection of Public Places -- Disposal and Disinfection of PPEs -- WATER TREATMENT AND WASTE MANAGEMENT -- Management of Water and Faecal Waste -- Safety of Water Supplies -- SOCIAL MEASURES -- Physical Distancing -- Quarantine and Isolation -- Home Quarantine -- Institutional Quarantine -- Staff Guidelines -- Utility Guidelines -- Lockdown and Travel Restrictions -- Zonal Classification of the Geography -- PROPHYLAXIS FOR COVID-19 -- Dietary Recommendations for the Prevention of COVID-19 -- General Measures -- Medicinal Plant Measures/Procedures -- Medical Prophylaxis for Healthcare Workers and Contacts of a Positive Patient -- REGULAR SCREENING -- PRECAUTIONS FOR TRAVEL -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Current Treatment Methods for Coronavirus Disease-19 -- Kuldeep Kumar1, Sonal1, Pankaj Bhatia1, Dhandeep Singh1, Amteshwar S. Jaggi1 and Nirmal Singh1,* -- INTRODUCTION -- OVERVIEW OF VARIOUS TREATMENT STRATEGIES FOR COVID-19.
Hydroxychloroquine -- HCQ in Treatment of COVID-19 -- Remdesivir -- Remdesivir in Treatment of COVID-19 -- Lopinavir/Ritonavir -- Lopinavir/Ritonavir in Treatment of COVID-19 -- Favipiravir -- Favipiravir in Treatment of COVID-19 -- Azithromycin (AZ) -- AZ in COVID-19 Treatment -- Arbidol -- Arbidol in Treatment of COVID-19 -- Ribavirin -- Ribavirin in COVID-19 Treatment -- Teicoplanin -- Teicoplanin in COVID-19 Treatment -- Ivermectin -- Ivermectin in Treatment of COVID-19 -- Nitazoxanide -- Nitazoxanide in COVID-19 Treatment -- Corticosteroids -- Corticosteroids in the Treatment of COVID-19 -- Immuno Modulating Agents-Interferons (IFN's) -- IFN's in Treatment of COVID-19 -- Monoclonal Antibody Therapy -- 80R Immunoglobulin G1 (IgGI) -- CR3014 -- Monoclonal Antibody Therapy in COVID-19 Treatment -- Tocilizumab -- Sarilumab -- Limitations and Suggestions Regarding mAb's -- Triple Therapy -- Miscellaneous Drugs -- Herbal Drugs for COVID-19 -- Glycyrrhizin -- Glycyrrhizin in COVID-19 -- Hesperetin -- Baicalin -- Scutellarin -- Plasma Therapy -- Plasma Therapy in the Treatment of COVID-19 -- Potential of Stem Cell Therapy in COVID-19 -- BCG Vaccine -- VARIOUS REGULATORY GUIDELINES GIVEN BY NIH (NATIONAL INSTITUTE OF HEALTH) FOR TREATMENT OF COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- AUTHORS CONTRIBUTION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Mortality -- Rimesh Pal1 and Sanjay Kumar Bhadada1,* -- INTRODUCTION -- REPRESENTING MORTALITY - MORTALITY RATE VS. CASE-FATALITY RATE -- FALLACIES IN ESTIMATING MORTALITY USING CASE-FATALITY RATE -- REPORTING COVID-19-RELATED DEATHS -- COMPARING CASE-FATALITY RATES OF COVID-19 WITH OTHER RELATED VIRAL DISEASES -- COMPARING COVID-19 CASE-FATALITY RATES AMONG VARIOUS NATIONS -- CAUSES OF DEATH IN COVID-19.
PARAMETERS PREDICTING MORTALITY IN COVID-19 -- Clinical Parameters -- Age -- Gender -- Symptoms -- Complications -- Comorbid Illness -- Smoking -- Secondary Infections -- Laboratory Parameters -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Long Term Complications of COVID-19 -- Ankita Sood1, Bimlesh Kumar1,*, Indu Melkani1, Archit Sood2, Pankaj Prashar1, Anamika Gautam1, Kardam Joshi3 and Dhara Patel3 -- INTRODUCTION -- LONG TERM COMPLICATIONS OF COVID-19 -- COMPLICATIONS OF COVID-19 IN VARIOUS DISEASES -- Diabetes Mellitus (DM) -- Hematological Complications -- Cardiovascular Diseases -- Central Nervous System Complications -- Viral Encephalitis -- Infectious Toxic Encephalopathy and Cerebrovascular Disease -- Chronic Kidney Disease (CKD) -- Asthma and Respiratory Disorders -- Rheumatoid Arthritis (RA) -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Vaccine Development -- Priya Sharma1,#, Shivani Joshi1,#, Aishwarya Joshi1, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: VACCINE DEVELOPMENT -- COVID-19 VACCINE DEVELOPMENT: MODULATING THE HOST IMMUNE SYSTEM -- TYPES OF VACCINES AND THEIR CHARACTERISTICS -- Live-attenuated Virus and Inactivated Whole Virus Vaccines -- Subunit Vaccines -- Vaccines Based on Virus-like Particles (VLPs) -- Viral Vector-based Vaccines -- DNA Vaccines -- NOVEL APPROACHES: USAGE OF MULTIDISCIPLINARY FIELDS -- Serum Albumin Strategy -- Natural Product (Plant) Based Technology -- Nanotechnology and Material Science -- mRNA Based Approaches -- ANIMAL MODELS TO TEST THE IMMUNOGENIC POTENTIAL OF CANDIDATE VACCINE ANTIGENS -- Animal Models Currently in Practice -- Humanized Mice Models -- Novel Approach of Using Zebrafish (Their Advantages) -- CURRENT STATUS OF VACCINE DEVELOPMENT.
BENCH TO BEDSIDE: OBSTACLES AND OUTCOMES -- Lessons from Previous Vaccine Development -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Future of COVID-19 Treatment -- Sahil Arora1,#, Manvendra Kumar1,#, Gaurav Joshi1,* and Raj Kumar1,* -- INTRODUCTION -- DRUGS AFFECTING VIRAL REPLICATION AND TRANSLATION IN COVID-19 DISEASE -- DRUGS INTERFERING WITH INFLAMMATION AND OVERCOMING CYTOKINE STORM IN COVID-19 DISEASE -- ANTICANCER DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- ANTIPARASITIC, ANTIPROTOZOAL, AND ANTIFUNGAL DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- DRUGS AFFECTING THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN COVID-19 -- MISCELLANEOUS -- DISCUSSION AND CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover.
Record Nr. UNINA-9910794531603321
Mittal Neeraj  
Sharjah : , : Bentham Science Publishers, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
COVID-19
COVID-19
Autore Mittal Neeraj
Edizione [1st ed.]
Pubbl/distr/stampa Sharjah : , : Bentham Science Publishers, , 2021
Descrizione fisica 1 online resource (223 pages)
Disciplina 616.2414
Altri autori (Persone) BhadadaSanjay K
KatareO. P
Soggetto topico COVID-19 (Disease) - Prevention
COVID-19 (Disease) - Economic aspects
COVID-19 (Disease) - Social aspects
COVID-19 Pandemic, 2020-
Soggetto non controllato Communicable Diseases
Medical
ISBN 1-68108-808-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Chapter 1 -- Sunishtha1, Govind Singh1 and Sanju Nanda1,* -- INTRODUCTION -- THE ATHENIAN PLAGUE -- PLAGUE OF JUSTINIAN -- THE BLACK DEATH -- SPANISH FLU -- AIDS -- SMALLPOX -- SARS -- SWINE FLU OR H1N1 PANDEMIC -- EBOLA -- COVID-19 -- ORIGIN OF CORONAVIRUS -- TYPES OF CORONAVIRUSES -- DISEASE ASSOCIATED WITH CORONAVIRUSES -- MURINE HEPATITIS VIRUS (MHV) -- Central Nervous System -- Hepatitis -- Pneumonitis -- BOVINE CORONAVIRUS -- HUMAN CORONAVIRUS -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 2 -- Hitesh Malhotra1,*, Anjoo Kamboj1 and Peeyush Kaushik1 -- INTRODUCTION -- GENOMIC STRUCTURE OF CORONAVIRUS -- STRUCTURAL PROTEINS -- Spike Protein -- Small Membrane Protein -- Membrane Protein -- Hemagglutinin-Esterase -- Nucleocapsid and Internal Proteins -- Replicase Protein -- VIRAL CYCLE -- OUTBREAKS OF CORONAVIRUS -- Porcine Coronavirus -- Avian Coronavirus -- Feline Coronavirus -- Bovine Coronavirus -- Murine Coronavirus -- Human Coronavirus -- SARS-CoV -- MERS-CoV -- COVID-19 -- Introduction -- Chronology of COVID-19 -- Symptoms -- Transmission -- Treatment -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 3 -- Kamya Goyal1,2,#, Shammy Jindal1,#, Tarun Kumar3, Jugnu Goyal4, Reena Sharma5, Ravinder Singh6 and Samir Mehndiratta7,8,* -- INTRODUCTION -- GEOGRAPHICAL DISTRIBUTION -- GLOBAL EPIDEMIOLOGY OF COVID-19 -- Effect of Age, Sex and other Factors on Covid-19-Related Deaths -- COVID-19 CASE COMPARISONS IN DIFFERENT REGION OF WORLD (WORLD HEALTH ORGANIZATION, 2020) -- COVID-19 IN INDIA -- REPORT BY ICMR ON COVID-19 ABOUT CONTAINMENT ZONE IN INDIA -- NATIONAL RESPONSES ON COVID-19 WORLDWIDE.
Asia -- China -- South Korea -- Middle Eastern -- Iran -- Europe -- Spain -- France -- North America -- United States -- South America -- Africa -- Oceania -- EFFECT OF LOCKDOWN ON COVID-19 CASES IN TOP TEN MOST AFFECTED COUNTRIES OF WORLD -- THE ROLE OF WHO AND INGOS FOR PROVIDING DATA IN COVID-19 -- OUTCOMES FROM SOME PUBLISHED REPORTS ON COVID-19 EPIDEMIOLOGY -- Herd Immunity-COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 4 -- Anirban Ghosh1 and Shamsher Singh1,* -- INTRODUCTION -- TRANSMISSION OF COV -- Virus Life Cycle -- Role of Structural Proteins in The Pathogenesis -- A. Spike Protein -- B. Hemagglutinin-Esterase (HE) Protein -- C. Membrane (M) Protein -- D. Small Envelop (E) Protein -- E. Nucleocapsid (N) Protein and Internal (I) Protein -- F. Replicase Proteins -- G. CoV Associated Protein -- Pathophysiology from a Cell Biology Perspective -- Phase I. Asymptomatic Stage (First 1-2 Days of Infection) -- Phase II. Upper Airway and Conducting Airway Response (Next Few Days) -- Phase III. Hypoxia, Ground-glass Infiltrates, Progression to ARDs -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 5 -- Jasleen Kaur1, Baljinder Singh2, Bikash Medhi3 and Gurpreet Kaur1,* -- INTRODUCTION -- CLINICAL PRESENTATIONS OF COVID-19 INFECTION -- INTER-INDIVIDUAL VARIATIONS IN CLINICAL PRESENTATIONS DUE TO DIFFERENTIAL SUSCEPTIBILITY TOWARDS COVID-19 -- Neonates or Newborns (Upto 1 Month) -- Infants (1 Month-2 Years), Children (2-10 Years) -- Adolescent (11-19 Years), Young (20-35 Years) and Middle Aged (36-59 Years) Patients -- Elderly (> -- 60 Years) and Older (> -- 80 Years) Patients -- ACE2 -- Gender -- Blood Group -- Previous Immunization -- COMORBIDITY -- CONCLUSION.
LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 6 -- Richa Deshpande1,#, Aishwarya Joshi1,#, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: A PANDEMIC DISEASE -- COVID-19: EARLY DETECTION BASED ON SYMPTOMS -- Clinical Analysis -- Hematological Analysis -- Chest CT -- COVID-19: MOLECULAR DETECTION OF VIRUS -- RT-PCR Based Assays -- Loop Mediated Isothermal Amplification (LAMP) -- CRISPR-Isothermal Amplification Based Assays -- Microarrays -- Metagenomic Sequencing Based Methods -- Gold Nanoparticles-Based Colorimetric Assay -- COVID-19: SERIOLOGICAL AND IMMUNOLOGICAL BASED DETECTION -- BIOMARKER IDENTIFICATION: APPROACH OF SEROLOGICAL PLATFORM -- Antibody Biomarkers -- Antigen Biomarkers -- Procalcitonin and Interleukin-6 as Prognostic COVID-19 Biomarkers -- SEROLOGICAL AND IMMUNOLOGICAL ASSAYS -- Enzyme-linked Immunosorbent Assay (ELISA) -- Lateral Flow Immunoassay -- Neutralization Assays -- Luminescence-based Immunoassays -- Biosensor Tests -- Rapid Antigen Tests -- CONCLUDING REMARKS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index.
Altri titoli varianti COVID-19
Record Nr. UNINA-9910794540303321
Mittal Neeraj  
Sharjah : , : Bentham Science Publishers, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
COVID-19
COVID-19
Autore Mittal Neeraj
Edizione [1st ed.]
Pubbl/distr/stampa Sharjah : , : Bentham Science Publishers, , 2021
Descrizione fisica 1 online resource (223 pages)
Disciplina 616.2414
Altri autori (Persone) BhadadaSanjay K
KatareO. P
Soggetto topico COVID-19 (Disease) - Prevention
COVID-19 (Disease) - Economic aspects
COVID-19 (Disease) - Social aspects
COVID-19 Pandemic, 2020-
Soggetto non controllato Communicable Diseases
Medical
ISBN 1-68108-808-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Chapter 1 -- Sunishtha1, Govind Singh1 and Sanju Nanda1,* -- INTRODUCTION -- THE ATHENIAN PLAGUE -- PLAGUE OF JUSTINIAN -- THE BLACK DEATH -- SPANISH FLU -- AIDS -- SMALLPOX -- SARS -- SWINE FLU OR H1N1 PANDEMIC -- EBOLA -- COVID-19 -- ORIGIN OF CORONAVIRUS -- TYPES OF CORONAVIRUSES -- DISEASE ASSOCIATED WITH CORONAVIRUSES -- MURINE HEPATITIS VIRUS (MHV) -- Central Nervous System -- Hepatitis -- Pneumonitis -- BOVINE CORONAVIRUS -- HUMAN CORONAVIRUS -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 2 -- Hitesh Malhotra1,*, Anjoo Kamboj1 and Peeyush Kaushik1 -- INTRODUCTION -- GENOMIC STRUCTURE OF CORONAVIRUS -- STRUCTURAL PROTEINS -- Spike Protein -- Small Membrane Protein -- Membrane Protein -- Hemagglutinin-Esterase -- Nucleocapsid and Internal Proteins -- Replicase Protein -- VIRAL CYCLE -- OUTBREAKS OF CORONAVIRUS -- Porcine Coronavirus -- Avian Coronavirus -- Feline Coronavirus -- Bovine Coronavirus -- Murine Coronavirus -- Human Coronavirus -- SARS-CoV -- MERS-CoV -- COVID-19 -- Introduction -- Chronology of COVID-19 -- Symptoms -- Transmission -- Treatment -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 3 -- Kamya Goyal1,2,#, Shammy Jindal1,#, Tarun Kumar3, Jugnu Goyal4, Reena Sharma5, Ravinder Singh6 and Samir Mehndiratta7,8,* -- INTRODUCTION -- GEOGRAPHICAL DISTRIBUTION -- GLOBAL EPIDEMIOLOGY OF COVID-19 -- Effect of Age, Sex and other Factors on Covid-19-Related Deaths -- COVID-19 CASE COMPARISONS IN DIFFERENT REGION OF WORLD (WORLD HEALTH ORGANIZATION, 2020) -- COVID-19 IN INDIA -- REPORT BY ICMR ON COVID-19 ABOUT CONTAINMENT ZONE IN INDIA -- NATIONAL RESPONSES ON COVID-19 WORLDWIDE.
Asia -- China -- South Korea -- Middle Eastern -- Iran -- Europe -- Spain -- France -- North America -- United States -- South America -- Africa -- Oceania -- EFFECT OF LOCKDOWN ON COVID-19 CASES IN TOP TEN MOST AFFECTED COUNTRIES OF WORLD -- THE ROLE OF WHO AND INGOS FOR PROVIDING DATA IN COVID-19 -- OUTCOMES FROM SOME PUBLISHED REPORTS ON COVID-19 EPIDEMIOLOGY -- Herd Immunity-COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 4 -- Anirban Ghosh1 and Shamsher Singh1,* -- INTRODUCTION -- TRANSMISSION OF COV -- Virus Life Cycle -- Role of Structural Proteins in The Pathogenesis -- A. Spike Protein -- B. Hemagglutinin-Esterase (HE) Protein -- C. Membrane (M) Protein -- D. Small Envelop (E) Protein -- E. Nucleocapsid (N) Protein and Internal (I) Protein -- F. Replicase Proteins -- G. CoV Associated Protein -- Pathophysiology from a Cell Biology Perspective -- Phase I. Asymptomatic Stage (First 1-2 Days of Infection) -- Phase II. Upper Airway and Conducting Airway Response (Next Few Days) -- Phase III. Hypoxia, Ground-glass Infiltrates, Progression to ARDs -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 5 -- Jasleen Kaur1, Baljinder Singh2, Bikash Medhi3 and Gurpreet Kaur1,* -- INTRODUCTION -- CLINICAL PRESENTATIONS OF COVID-19 INFECTION -- INTER-INDIVIDUAL VARIATIONS IN CLINICAL PRESENTATIONS DUE TO DIFFERENTIAL SUSCEPTIBILITY TOWARDS COVID-19 -- Neonates or Newborns (Upto 1 Month) -- Infants (1 Month-2 Years), Children (2-10 Years) -- Adolescent (11-19 Years), Young (20-35 Years) and Middle Aged (36-59 Years) Patients -- Elderly (> -- 60 Years) and Older (> -- 80 Years) Patients -- ACE2 -- Gender -- Blood Group -- Previous Immunization -- COMORBIDITY -- CONCLUSION.
LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 6 -- Richa Deshpande1,#, Aishwarya Joshi1,#, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: A PANDEMIC DISEASE -- COVID-19: EARLY DETECTION BASED ON SYMPTOMS -- Clinical Analysis -- Hematological Analysis -- Chest CT -- COVID-19: MOLECULAR DETECTION OF VIRUS -- RT-PCR Based Assays -- Loop Mediated Isothermal Amplification (LAMP) -- CRISPR-Isothermal Amplification Based Assays -- Microarrays -- Metagenomic Sequencing Based Methods -- Gold Nanoparticles-Based Colorimetric Assay -- COVID-19: SERIOLOGICAL AND IMMUNOLOGICAL BASED DETECTION -- BIOMARKER IDENTIFICATION: APPROACH OF SEROLOGICAL PLATFORM -- Antibody Biomarkers -- Antigen Biomarkers -- Procalcitonin and Interleukin-6 as Prognostic COVID-19 Biomarkers -- SEROLOGICAL AND IMMUNOLOGICAL ASSAYS -- Enzyme-linked Immunosorbent Assay (ELISA) -- Lateral Flow Immunoassay -- Neutralization Assays -- Luminescence-based Immunoassays -- Biosensor Tests -- Rapid Antigen Tests -- CONCLUDING REMARKS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index.
Altri titoli varianti COVID-19
Record Nr. UNINA-9910817553703321
Mittal Neeraj  
Sharjah : , : Bentham Science Publishers, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
COVID-19
COVID-19
Autore Mittal Neeraj
Edizione [1st ed.]
Pubbl/distr/stampa Sharjah : , : Bentham Science Publishers, , 2021
Descrizione fisica 1 online resource (225 pages)
Disciplina 362.1962414
Altri autori (Persone) BhadadaSanjay Kumar
KatareO. P
Soggetto topico Covid-19 vaccines
Public policy
Soggetto non controllato Communicable Diseases
Medical
ISBN 1-68108-805-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Prevention of COVID-19: Facts to Overcome the Myths -- Rajesh Kumar1, Mangesh Pradeep Kulkarni1, Sheetu Wadhwa1 and Soundappan Kathirvel2,* -- INTRODUCTION -- MEASURES TO PREVENT THE SPREAD, ASSOCIATED MYTHS AND FACTS -- Personal Protective Equipment (PPE) -- Head Covers -- Face Shield -- Mask -- Goggles -- Gloves -- Shoe Covers -- Gowns or Coveralls -- SANITIZATION AND DISINFECTION -- Hand Hygiene -- For Public -- Prevention of COVID-19 Among Frontline Healthcare Workers -- Cleaning of Vegetables-Fruits -- Safe Handling of Currency and Paper Documents -- Cough or Respiratory Etiquettes -- Precautions to be Taken While Coughing/Sneezing or Any Physical Contact -- Spitting or Littering in Public -- Disinfection of Public Places -- Disposal and Disinfection of PPEs -- WATER TREATMENT AND WASTE MANAGEMENT -- Management of Water and Faecal Waste -- Safety of Water Supplies -- SOCIAL MEASURES -- Physical Distancing -- Quarantine and Isolation -- Home Quarantine -- Institutional Quarantine -- Staff Guidelines -- Utility Guidelines -- Lockdown and Travel Restrictions -- Zonal Classification of the Geography -- PROPHYLAXIS FOR COVID-19 -- Dietary Recommendations for the Prevention of COVID-19 -- General Measures -- Medicinal Plant Measures/Procedures -- Medical Prophylaxis for Healthcare Workers and Contacts of a Positive Patient -- REGULAR SCREENING -- PRECAUTIONS FOR TRAVEL -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Current Treatment Methods for Coronavirus Disease-19 -- Kuldeep Kumar1, Sonal1, Pankaj Bhatia1, Dhandeep Singh1, Amteshwar S. Jaggi1 and Nirmal Singh1,* -- INTRODUCTION -- OVERVIEW OF VARIOUS TREATMENT STRATEGIES FOR COVID-19.
Hydroxychloroquine -- HCQ in Treatment of COVID-19 -- Remdesivir -- Remdesivir in Treatment of COVID-19 -- Lopinavir/Ritonavir -- Lopinavir/Ritonavir in Treatment of COVID-19 -- Favipiravir -- Favipiravir in Treatment of COVID-19 -- Azithromycin (AZ) -- AZ in COVID-19 Treatment -- Arbidol -- Arbidol in Treatment of COVID-19 -- Ribavirin -- Ribavirin in COVID-19 Treatment -- Teicoplanin -- Teicoplanin in COVID-19 Treatment -- Ivermectin -- Ivermectin in Treatment of COVID-19 -- Nitazoxanide -- Nitazoxanide in COVID-19 Treatment -- Corticosteroids -- Corticosteroids in the Treatment of COVID-19 -- Immuno Modulating Agents-Interferons (IFN's) -- IFN's in Treatment of COVID-19 -- Monoclonal Antibody Therapy -- 80R Immunoglobulin G1 (IgGI) -- CR3014 -- Monoclonal Antibody Therapy in COVID-19 Treatment -- Tocilizumab -- Sarilumab -- Limitations and Suggestions Regarding mAb's -- Triple Therapy -- Miscellaneous Drugs -- Herbal Drugs for COVID-19 -- Glycyrrhizin -- Glycyrrhizin in COVID-19 -- Hesperetin -- Baicalin -- Scutellarin -- Plasma Therapy -- Plasma Therapy in the Treatment of COVID-19 -- Potential of Stem Cell Therapy in COVID-19 -- BCG Vaccine -- VARIOUS REGULATORY GUIDELINES GIVEN BY NIH (NATIONAL INSTITUTE OF HEALTH) FOR TREATMENT OF COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- AUTHORS CONTRIBUTION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Mortality -- Rimesh Pal1 and Sanjay Kumar Bhadada1,* -- INTRODUCTION -- REPRESENTING MORTALITY - MORTALITY RATE VS. CASE-FATALITY RATE -- FALLACIES IN ESTIMATING MORTALITY USING CASE-FATALITY RATE -- REPORTING COVID-19-RELATED DEATHS -- COMPARING CASE-FATALITY RATES OF COVID-19 WITH OTHER RELATED VIRAL DISEASES -- COMPARING COVID-19 CASE-FATALITY RATES AMONG VARIOUS NATIONS -- CAUSES OF DEATH IN COVID-19.
PARAMETERS PREDICTING MORTALITY IN COVID-19 -- Clinical Parameters -- Age -- Gender -- Symptoms -- Complications -- Comorbid Illness -- Smoking -- Secondary Infections -- Laboratory Parameters -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Long Term Complications of COVID-19 -- Ankita Sood1, Bimlesh Kumar1,*, Indu Melkani1, Archit Sood2, Pankaj Prashar1, Anamika Gautam1, Kardam Joshi3 and Dhara Patel3 -- INTRODUCTION -- LONG TERM COMPLICATIONS OF COVID-19 -- COMPLICATIONS OF COVID-19 IN VARIOUS DISEASES -- Diabetes Mellitus (DM) -- Hematological Complications -- Cardiovascular Diseases -- Central Nervous System Complications -- Viral Encephalitis -- Infectious Toxic Encephalopathy and Cerebrovascular Disease -- Chronic Kidney Disease (CKD) -- Asthma and Respiratory Disorders -- Rheumatoid Arthritis (RA) -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Vaccine Development -- Priya Sharma1,#, Shivani Joshi1,#, Aishwarya Joshi1, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: VACCINE DEVELOPMENT -- COVID-19 VACCINE DEVELOPMENT: MODULATING THE HOST IMMUNE SYSTEM -- TYPES OF VACCINES AND THEIR CHARACTERISTICS -- Live-attenuated Virus and Inactivated Whole Virus Vaccines -- Subunit Vaccines -- Vaccines Based on Virus-like Particles (VLPs) -- Viral Vector-based Vaccines -- DNA Vaccines -- NOVEL APPROACHES: USAGE OF MULTIDISCIPLINARY FIELDS -- Serum Albumin Strategy -- Natural Product (Plant) Based Technology -- Nanotechnology and Material Science -- mRNA Based Approaches -- ANIMAL MODELS TO TEST THE IMMUNOGENIC POTENTIAL OF CANDIDATE VACCINE ANTIGENS -- Animal Models Currently in Practice -- Humanized Mice Models -- Novel Approach of Using Zebrafish (Their Advantages) -- CURRENT STATUS OF VACCINE DEVELOPMENT.
BENCH TO BEDSIDE: OBSTACLES AND OUTCOMES -- Lessons from Previous Vaccine Development -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Future of COVID-19 Treatment -- Sahil Arora1,#, Manvendra Kumar1,#, Gaurav Joshi1,* and Raj Kumar1,* -- INTRODUCTION -- DRUGS AFFECTING VIRAL REPLICATION AND TRANSLATION IN COVID-19 DISEASE -- DRUGS INTERFERING WITH INFLAMMATION AND OVERCOMING CYTOKINE STORM IN COVID-19 DISEASE -- ANTICANCER DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- ANTIPARASITIC, ANTIPROTOZOAL, AND ANTIFUNGAL DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- DRUGS AFFECTING THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN COVID-19 -- MISCELLANEOUS -- DISCUSSION AND CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover.
Record Nr. UNINA-9910825895903321
Mittal Neeraj  
Sharjah : , : Bentham Science Publishers, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The COVID-19 pandemic : epidemiology, molecular biology and therapy / / edited by Shama Parveen
The COVID-19 pandemic : epidemiology, molecular biology and therapy / / edited by Shama Parveen
Pubbl/distr/stampa Singapore : , : Bentham Science Publishers, , [2021]
Descrizione fisica 1 online resource (276 pages)
Disciplina 614.592414
Soggetto topico Coronavirus infections
Soggetto non controllato Communicable Diseases
Medical
ISBN 981-14-8187-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910794438803321
Singapore : , : Bentham Science Publishers, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The COVID-19 pandemic : epidemiology, molecular biology and therapy / / edited by Shama Parveen
The COVID-19 pandemic : epidemiology, molecular biology and therapy / / edited by Shama Parveen
Pubbl/distr/stampa Singapore : , : Bentham Science Publishers, , [2021]
Descrizione fisica 1 online resource (276 pages)
Disciplina 614.592414
Soggetto topico Coronavirus infections
Soggetto non controllato Communicable Diseases
Medical
ISBN 981-14-8187-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910828840903321
Singapore : , : Bentham Science Publishers, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Current HIV/AIDS reports
Current HIV/AIDS reports
Pubbl/distr/stampa [Philadelphia, Pa.] : , : Current Science, , 2004-
Disciplina 614.5
Soggetto topico AIDS (Disease)
HIV infections
Soggetto genere / forma Periodicals.
Soggetto non controllato Communicable Diseases
ISSN 1548-3576
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Record Nr. UNINA-9910143072103321
[Philadelphia, Pa.] : , : Current Science, , 2004-
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Current HIV/AIDS reports
Current HIV/AIDS reports
Pubbl/distr/stampa [Philadelphia, Pa.] : , : Current Science, , 2004-
Disciplina 614.5
Soggetto topico AIDS (Disease)
HIV infections
Soggetto genere / forma Periodicals.
Soggetto non controllato Communicable Diseases
ISSN 1548-3576
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Record Nr. UNISA-996198110103316
[Philadelphia, Pa.] : , : Current Science, , 2004-
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
Emerging microbes & infections
Emerging microbes & infections
Pubbl/distr/stampa New York, : NPG, 2012-2018
Descrizione fisica 1 online resource
Soggetto topico Emerging infectious diseases
Emerging infectious diseases - Pathogenesis
Emerging infectious diseases - Epidemiology
Communicable Diseases, Emerging
Soggetto genere / forma Fulltext
Internet Resources.
Periodicals.
Periodical
Soggetto non controllato Communicable Diseases
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti EMI
Emerging microbes and infections
Record Nr. UNINA-9910133836803321
New York, : NPG, 2012-2018
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Emerging microbes & infections
Emerging microbes & infections
Pubbl/distr/stampa New York, : NPG, 2012-2018
Descrizione fisica 1 online resource
Soggetto topico Emerging infectious diseases
Emerging infectious diseases - Pathogenesis
Emerging infectious diseases - Epidemiology
Communicable Diseases, Emerging
Soggetto genere / forma Fulltext
Internet Resources.
Periodicals.
Periodical
Soggetto non controllato Communicable Diseases
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti EMI
Emerging microbes and infections
Record Nr. UNISA-996321888703316
New York, : NPG, 2012-2018
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui